Montelukast and Coronavirus Disease 2019: A Scoping Review

Niusha Sharifinejad; Samin Sharafian; Sana Salekmoghadam; Marzieh Tavakol; Mostafa Qorbani

doi:10.18502/ijaai.v20i4.6948

Niusha Sharifinejad Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran
Samin Sharafian Department of Allergy and Clinical Immunology, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Sana Salekmoghadam Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran
Marzieh Tavakol Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
Mostafa Qorbani Social Determinants of Health Research Center, Alborz University \of Medical Sciences, Karaj, Iran

DOI: https://doi.org/10.18502/ijaai.v20i4.6948

Keywords: COVID-19; Leukotriene antagonists; Leukotriene D4 receptor; Montelukast; SARS-CoV-2

Abstract

Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19. Montelukast (MK) is a safe asthma controller drug, which is considered as a potential antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review has a systematic approach to investigate the reports on the use of MK as a part of treatment or a prophylactic agent in COVID-19. The search was conducted in PubMed, Web of Science, and Scopus databases and yielded 35 studies containing the influence of MK on SARS-CoV-2. Ultimately, MK appears to be worth being used as an adjuvant therapeutic and prophylactic drug against SARS-CoV-2. Nevertheless, more clinical trials are required to accurately investigate its effectiveness.